key: cord-0766175-jhraafm2 authors: Melissa, Haendel; Christopher, Chute; Kenneth, Gersing title: The National COVID Cohort Collaborative (N3C): Rationale, Design, Infrastructure, and Deployment date: 2020-08-17 journal: J Am Med Inform Assoc DOI: 10.1093/jamia/ocaa196 sha: c4dcab80076f379b6be18861611238fcbc5eda31 doc_id: 766175 cord_uid: jhraafm2 OBJECTIVE: COVID-19 poses societal challenges that require expeditious data and knowledge sharing. Though organizational clinical data are abundant, these are largely inaccessible to outside researchers. Statistical, machine learning, and causal analyses are most successful with large-scale data beyond what is available in any given organization. Here, we introduce the National COVID Cohort Collaborative (N3C), an open science community focused on analyzing patient-level data from many centers. METHODS: The Clinical and Translational Science Award (CTSA) Program and scientific community created N3C to overcome technical, regulatory, policy, and governance barriers to sharing and harmonizing individual-level clinical data. We developed solutions to extract, aggregate, and harmonize data across organizations and data models, and created a secure data enclave to enable efficient, transparent, and reproducible collaborative analytics. Organized in inclusive workstreams, in two months we created: legal agreements and governance for organizations and researchers; data extraction scripts to identify and ingest positive, negative, and possible COVID-19 cases; a data quality assurance and harmonization pipeline to create a single harmonized dataset; population of the secure data enclave with data, machine learning, and statistical analytics tools; dissemination mechanisms; and a synthetic data pilot to democratize data access. DISCUSSION: The N3C has demonstrated that a multi-site collaborative learning health network can overcome barriers to rapidly build a scalable infrastructure incorporating multi-organizational clinical data for COVID-19 analytics. We expect this effort to save lives by enabling rapid collaboration among clinicians, researchers, and data scientists to identify treatments and specialized care and thereby reduce the immediate and long-term impacts of COVID-19. LAY SUMMARY: COVID-19 poses societal challenges that require expeditious data and knowledge sharing. Though medical records are abundant, they are largely inaccessible to outside researchers. Statistical, machine learning, and causal research are most successful with large datasets beyond what is available in any given organization. Here, we introduce the National COVID Cohort Collaborative (N3C), an open science community focused on analyzing patient-level data from many clinical centers to reveal patterns in COVID-19 patients. To create N3C, the community had to overcome technical, regulatory, policy, and governance barriers to sharing patient-level clinical data. In less than 2 months, we developed solutions to acquire and harmonize data across organizations and created a secure data environment to enable transparent and reproducible collaborative research. We expect the N3C to help save lives by enabling collaboration among clinicians, researchers, and data scientists to identify treatments and specialized care needs and thereby reduce the immediate and long-term impacts of COVID-19. participating organizations using a common data model (CDM) . These networks are a vital resource for responding to the COVID-19 crisis, revealing key patterns in the disease [9, 10] . However, their distributed nature would greatly complicate certain types of analyses that require a centralized approach to enable timely analyses. Study questions and data queries that can be pre-specified, such as testing for associations between one or a group of comorbidities and laboratory results, are often answerable using federated networks. In contrast, centralized resources can greatly simplify implementation of iterative processes such as training deep learning algorithms and carrying out clustering for phenotype development. [11] [12] [13] [14] A centralized resource also enables rapid integration with knowledge graphs and other translational knowledge and data sources to aid discovery, prioritization, and weighting of results. Federated machine learning algorithms will likely ultimately play important roles in allowing model training on distributed datasets [15] [16] [17] [18] [19] . While these methods show great promise, we have chosen not to pursue this approach at this time to avoid adding complexity to an already ambitious project. Creating a massive corpus of harmonized EHR data for analytics would support rapid collaboration and discovery, and also build upon the substantial resources (e.g. CDM-specific data quality tools, etc.) developed within the federated consortia. The recent retractions in the Lancet [20] and the New England Journal of Medicine [21] have underscored the need for fully provenanced and reproducible EHR analyses as major policy decisions that can hinge on EHR results. Moreover, the pathway for obtaining permissions to reuse data must be clear and well-documented. The ideal data resources are FAIR (findable, accessible, interoperable, reusable), particularly in a pandemic where analyses must be fast, verifiable, and based on the latest data [22] . The National COVID Cohort Collaborative (N3C; covid.cd2h.org) aims to aggregate and harmonize EHR data across clinical organizations in the United States (US), especially the Clinical and Translational Science Awards (CTSA) Program hubs that encompass more than 60 organizations and their partners [23] . In just two months, the N3C was built on a foundation of established, productive research communities and their existing resources. It comprises a collaborative network of more than 600 individuals and 100 organizations and is growing. N3C enables broad access and analytics of harmonized EHR data, demonstrating a novel approach for collaborative data sharing that could transcend current and future health emergencies. The primary features of N3C are: national collaboration and governance, regulatory strategies, COVID-19 cohort definitions via community-developed phenotypes, data harmonization across four CDMs, and development of a collaborative analytics platform to support deployment of novel algorithms of data aggregated from the US. The N3C supports community-driven, reproducible, and transparent analyses with COVID-19 data, promoting rapid dissemination of results and atomic attribution and demonstrating that open science can be effectively implemented on EHR data at scale. N3C is built upon principles of partnership, inclusivity, transparency, reciprocity, accountability, and security: • Partnership: N3C members are trusted partners committed to honoring the N3C Community Guiding Principles and User Code of Conduct. • Inclusivity: N3C is open to any organization that wishes to contribute data. N3C also welcomes registered researchers who follow our governance processes, including citizen and community scientists, to access the data. • Transparency: Open and reproducible research is the hallmark of N3C. Access to data is project-based. Descriptions of projects are posted and searchable to promote collaborations. • Reciprocity: Contributions are acknowledged and results from analyses, including provenance and attribution, are expected to be shared with the N3C community. • Accountability: N3C members take responsibility for their activity and hold each other accountable for achieving N3C objectives. • Security: Activities are conducted in a secure, controlled-access, cloud-based environment, and are recorded for auditing and attribution purposes. The analytics platform or N3C Enclave, hosted by a secure National Center for Advancing Translational Science (NCATS)-controlled cloud environment, includes clinical data from patients who meet criteria in the N3C COVID-19 phenotype from sites across the US dating back to January 2018 [24] . Privacy-preserving record linkage will be developed to allow association with additional regulatory approvals to other datasets, such as imaging, genomic, or clinical trial data. Additionally, N3C will pilot the creation of algorithmically-derived synthetic data sets. The N3C data is available to researchers to conduct a broad range of COVID-19-related analyses. N3C activities are divided into five workstreams as shown in Figure 1 . The Data Partnership and Governance Workstream focuses on collaboratively developing a governance framework to support open science, while preserving patient privacy and promoting ethical research. With this goal in mind we borrowed best practices from prior work including centralized data sharing models (All of Us Research Program researcher hub [28] , Human Tumor Atlas Network [29] , the Synapse platform [30] [31] [32] [33] [34] [35] ) and consulted governance frameworks of other networks (Global Alliance for Genomics and Health [36] , International Cancer Genome Consortium [37] , ACT Network [38] ). The N3C governance framework was drafted and refined iteratively with feedback from partners, especially from sites contributing data. This framework is composed of interlocking elements: (1) a secure analytic environment; (2) governing documents; (3) data transfer and access request processes and the Data Access Committee; (4) community guiding principles; and (5) an attribution and publication policy. The regulatory steps for organizations and users are shown in Figure 2 , which provides details on the many layers of security, approvals, and policy-meeting required to ensure the dual goals of the highest security for and broad usage of the data. N3C supports four tiers of data: HIPAA limited data, HIPAA Safe-harbor data, aggregate data, and synthetic data[39,40] (see Table 1 ). N3C has designed and tested processes and protocols to protect sensitive data and provide ethical and regulatory oversight. The N3C Enclave, which provides the only external access to the combined data set, is protected by a Certificate of Confidentiality [41] . This allows for granular access controls, activity auditing, and prevention of data downloads. NCATS acts as the data steward on behalf of contributing organizations. Shared expectations and trust are essential for the success of the N3C community. Our goal is to ensure that N3C provides the ability to easily engage and onboard to a collaborative environment, for the broadest possible community. To this end, the workstream developed Community Guiding Principles (CGP), which describe behavioral and ethical expectations, our diversity statement, and a conflict resolution process. The Data Partnership and Governance Workstream worked closely with NCATS to develop two governing agreements: the Data Transfer Agreement (DTA), which is signed by contributing organizations and NCATS, and the Data Use Agreement (DUA), which is signed by accessing organizations and NCATS. Under the HIPAA Privacy Rule [40] , a limited dataset may be shared if an agreement exists between the disclosing and the receiving parties. The NCATS DTA and DUA meet these HIPAA requirements and include provisions prohibiting any attempts to reidentify the data or use it beyond COVID-19 research. The decision to cover data transfer and data use as separate agreements was intentional, as it allows organizations to access data even if they do not contribute data. Submission of data to N3C must be approved by an Institutional Review Board (IRB). To lower the burden associated with individual IRB submissions, and in accordance with the revised Common Rule [42] we established a central IRB at Johns Hopkins University School of Medicine (JHM) via the SMART IRB [43] Master Common Reciprocal reliance agreement. Contributing sites are encouraged to rely on the central IRB, but may choose to undergo review through their local IRB. This initial IRB approval is intended to cover only contribution of data to N3C and does not cover research using N3C data. The Data Partnership and Governance Workstream and NCATS collaboratively developed a Data Use Request (DUR) framework, with the dual aims of protecting patient data and ensuring a transparent process for data access. Our tiered approach to data access allows us to reduce regulatory burden on investigators, while ensuring appropriate regulatory approvals are in place. There are three tiers of access: Registered, Controlled, and Controlled-Plus as described in Table 1 . Investigators wishing to access the data must have an N3C user profile linked to a public Open Researcher and Contributor Identifier (ORCID) [44] . Access requirements and approval processes vary depending on the level of access requested. For each project for which a user wishes to access data, he or she must submit a DUR with their intended data use statement and include a non-confidential abstract of the research project that will be publicly posted within N3C for transparency and to encourage collaborations. Data requesters must also sign a User Code of Conduct to affirm their agreement to the N3C terms and conditions. The N3C Data Access Committee (DAC), composed of representatives from NIH with occasional consulting from N3C community members, will review the DUR and verify that the conditions for access (see Table 1 ) are met. The DAC's role is to evaluate DURs; it does not exist to evaluate the scientific merit of the project. Clinical data have high utility for COVID-19-related research; however, N3C recognizes the need to analyze clinical data along with data from other sources. Therefore, we will establish a privacy-preserving strategy to enable linkages within and external to the N3C data set. In this way, genomic, radiology, pathology imaging, and other data can be analyzed in conjunction with the N3C clinical data. It will also lay the groundwork for future studies to deduplicate patients. The purpose of this workstream is threefold: (1) to determine the data inclusion/exclusion criteria for import to N3C (computable phenotype); (2) to create and maintain a set of scripts to execute the computable phenotype in each of four CDMs-ACT, OMOP, PCORnet, and TriNetX-and extract relevant data for that cohort; and (3) to provide direct support to sites throughout the data acquisition process. Given our evolving understanding of COVID-19 signs and symptoms, it is challenging to define stable computable phenotypes that can accurately identify COVID-19 patients from their EHR data. To ensure that the data in N3C encompass these varied and fluctuating perspectives, we chose to bring together existing inclusion criteria and codesets from a number of organizations (e.g., CDC coding guidance [53, 54] , PCORnet [55] , OHDSI [56] , LOINC [57] , etc.) into a "best-ofbreed" phenotype. The draft phenotype was iterated within the N3C community and remains open to public comment. The N3C phenotype[58] is designed to be inclusive of any diagnosis codes, procedure codes, lab tests, or combination thereof that may be indicative of COVID-19, while still limiting the number of extracted records to meaningful and manageable levels (see Table 2 ). Notably, the N3C COVID-19 phenotype purposely includes patients who tested negative for COVID-19; thus inclusion in the N3C cohort is not equivalent to "positive for COVID-19," but rather "relevant for COVID-19-related analysis" as defined by their categorization as "lab-confirmed negative," "lab-confirmed positive," "suspected positive," or "possible positive" (see the N3C phenotype documentation[59] for detailed definitions of these categories). Once the N3C community agreed on the initial phenotype logic, the initial phenotype logic was translated into SQL to run against each of four common data models at participating sites: ACT, OMOP, PCORnet, and TriNetX. Multiple SQL dialects support the different relational database management systems in use. The use of existing CDMs allows for rapid startup and minimizes the burden of participation by contributing sites. Most CTSA sites and many other medical centers host one or more CDMs. In particular, the following four CDMs are frequent in these communities, and form the basis for data submission to N3C: • ACT Network: A federated network, data model, and ontology for CTSA sites that consists of i2b2 data repositories that are integrated by the SHRINE (Shared Health Research Information Network) [62] platform, focused on real time querying across sites [4] . Contributing organizations are expected to submit data using one of these models. N3C's SQL scripts serve two functions for participating sites: (1) to identify the qualifying patient cohort in a site's CDM of choice and store that cohort in a The guiding principle for these scripts is to minimize customization at the local site level. The workstream devised four different methods of data extraction and transfer (see Table 3 ), allowing sites to use the technology stack with which they are most comfortable, while complying with our guiding principles. Once a site joins N3C and is ready to contribute data, members of the Phenotype and Data Acquisition workstream make themselves available via web-based "office hours" to onboard the new site and explain the process for script execution and data transmission. Table 3 . Data extraction and transfer methods that sites may use to submit data to N3C. N3C aims to support consistency in the data acquisition process across the four CDMs. Simply aggregating those data together is insufficient. Not only does each model have different structures and values, but heterogeneity exists within models. The goal of the Data Ingestion and Harmonization workstream is to align and harmonize the syntax and semantics of data from all contributing sites into a single data model, retaining as much specificity and original clinical intent as possible as well as data quality and transparency. These steps support N3C's ultimate goal of producing comparable and consistent data to enable effective and efficient analytics [70, 71] . When a participating site submits a data payload to N3C, the data submission flows through an ETL pipeline that leverages the aforementioned mappings. The pipeline is powered by Adeptia [82] , a cloud-based Platform as a Service on the secure NCATS Amazon Web Services (AWS) production cloud. Prior to loading a given data payload into the production N3C database, the payload must first undergo a series of data quality checks as part of the ingestion process. This process, described below, ensures that any errors can be corrected, and that sitespecific idiosyncrasies can be accounted for and known to downstream users. In large data aggregation projects, where many sources combine to form a larger dataset, there are issues caused by the data heterogeneity which impact data quality (DQ) [83, 84] . DQ measures, including consistency, correctness, concordance, currency, and plausibility, are important to support analysis and computation [85, 86] . Many large-scale data aggregation projects benefit from focusing on a set of contextual use cases or a defined population research domain. [87] [88] [89] For N3C, we developed an approach to DQ that addresses the downstream application of the data for machine learning and statistical analytics . In order to establish a starting point, the N3C Data Ingestion and Harmonization workstream became familiar with a wide array of available DQ tools and processes. They met with SMEs from each of the source CDMs, focusing on the DQ approaches and tools employed in their native implementations (see Table 4 ). These native approaches became a foundation on which N3C could build its own DQ processes. (3) where in the ingestion pipeline DQ checks should be instantiated. In these discussions, the group agreed that a "light touch" was the best approach to DQ for N3C; to pass along the data as they are, and only in some cases make "cleaning" corrections. These cleaning steps would seek to correct the data only to the extent required to support computation and OMOP data model conformance. The exception to this is data related to COVID-19 tests, as we anticipate variance in how organizations code COVID-19 tests, particularly in the very early stages of the pandemic. Due to the criticality of these data for N3C, we corrected erroneous coding using text data indicating COVID-19 status, which would otherwise be lost. [97] To ensure that data loss was minimized in the data transformation process, we made the decision to retain the raw source data during and after the mapping and transformation process to preserve contextual details about the data for meta-analyses downstream. Additional detail about the N3C Data Quality Checks and ingestion process is provided in Figure 3 . The goals of the Collaborative Analytics workstream are to ensure secure stewardship of N3C data; design and disseminate analyses; integrate community tools and resources; provide tracking and attribution of users, results, and contributions; and enable novel approaches to data sharing ( Figure 4 ). A "data enclave" is a secure data and computing environment, designed to facilitate virtual access to hosted data with safeguards to prohibit or limit data export [98] . are also being made available, the first deployments are listed in Table 5 . The platform is certified as Federal Risk and Authorization Management Program (FedRAMP) Moderate [99] , a government security standard for unclassified but highly sensitive data. To enable research collaboration on sensitive EHR data, the N3C Enclave supports fine-grained access controls and auditing mechanisms, allowing multiple users to work securely in a single system. The system provides "limited realms", where users are granted access to specifically designated data and resources such as Limited DataSet (LDS) and Safe-Harbor data. Additional security and auditing mechanisms include the ability to limit patient-level data access, read and write access to data sets, and user access, auditing, and tracing. As outlined in Figure 2 , investigators have restricted access to LDS data without project specific IRB reviews. This is mediated by the designation of a few software agents, such as cross tabulation, logistic regression, mapping and other related visualizations, as having privileged access to the LDS data in a manner that 1) prohibits users from seeing the underlying patientlevel data, and 2) inhibits the display of tables or cells that comprise less than 10 patients. Through this enclave functionality, secure analyses of data containing limited PHI (LDS) can proceed without compromising privacy or confidentiality. The outputs from these specially designated software packages are regarded as results, and are not subject to human subjects data restrictions. Web-based cohort builder. Study feasibility for clinician investigators with limited informatics skills [112] ; hierarchical concepts and ontologies to construct SQL query building blocks, exposed by a simple drag-and-drop user interface. Transparency and reproducibility are fundamental to the prescribed use of the N3C Enclave [113] . The platform automatically builds a provenance graph for every dataset and analysis. Each artifact in the platform is stored as an immutable object, enabling full Git-like traceability on all changes. Each workflow includes extensive metadata describing all of the inputs, the user who triggered it, the build environment, and the required packages. Researchers can confidently share results as "reports," which include a precise record of how they were generated, allowing other researchers to replicate and build on the analyses. Key capabilities are: • Raw data provenance: Support for provenance capture of imported data, and recording of metadata for understanding the origins of each dataset. • Data lineages: Data transformations recorded as a dependency graph, enabling full (re)construction of data lineage. • Versioning: Data versioning, allowing full analytical reproducibility. • Validation and errors: Runtime characteristics monitored and recorded. The creation of synthetic clinical data represents a unique opportunity for N3C to more widely disseminate and provide greater utility for the N3C dataset. Current state-of-the-art approaches for the generation of synthetic clinical data can be broadly classified as: • Statistical simulation: Statistical models or profiles of normal human physiology and/or disease states are created based upon real-world data. The ensuing simulated patients and their data are generally consistent with population-level norms [114] [115] [116] . • Computational derivation: Computational models of real-world data are produced ondemand, which can be used to produce novel data in a multi-dimensional space (e.g., features) that adhere to the quantitative distributions and co-variance of the original source data. When generating these types of models, data content and statistical features are a function of the input dataset. The process can be repeated multiple times with the same source data producing multiple derivative synthetic datasets. Further, such computationally derived synthetic datasets do not share mutual information with source data, minimizing the potential for re-identification [45, 46, [117] [118] [119] . N3C has launched a pilot to evaluate the creation of synthetic data from the N3C LDS, and will focus on validating the synthetic data for key analyses against those performed on the LDS in areas such as identifying patients for whom COVID-19 testing can/should impact clinical management; anticipating severity of disease, risk of death, and potential response to therapies; and geospatial analytics for enhanced insights into geographic hotspots and for quantifying the contribution of zip code level SDoH in predictive analytics. The N3C architecture, dataset, and analytic environment is a powerful platform for developing machine learning algorithms, statistical models, and clinical decision support tools. Analytic models are able to use time series, clinical, and laboratory information to predict progression, [21, 121] . Attribution is native to the system, and supports the notion of transitive credit [52] for all contributors. Investigators are encouraged to pre-specify hypotheses or other study goals in a publicly-available and versioned study protocol and to maintain full documentation of all code and protocol revisions in order to mitigate the risk of p-hacking and promote the legibility and traceability of all major study design and analytic choices [122] . The N3C Enclave allows and, indeed, requires sharing of software, results, and methods. It is our belief that by allowing the research community to work together in this way, we aree able to rapidly increase our collective understanding of COVID-19 and identify effective approaches for prevention and treatment, ultimately curbing the effects of this pandemic on our nation and world. At the time of publication, there have been 49 DTAs executed, 27 IRB protocols approved (23 reliance, 4 local), and 11 institutions have deposited data within the N3C (5 PCORnet, 3 OMOP, 2 TriNetX, and 1 ACT). Overall, the cohort from the 11 sites to date represents 33K positive COVID-19 cases out of ~513K total patients. We anticipate ~150K positive cases to be included in the N3C Enclave by Sept. 1st, 2020. COVID-19 has proven to be a novel, heterogeneous disease, particularly in terms of range of symptoms and signs, severity and clinical course. By integrating data from multiple sites, we enable researchers to explore questions with vastly more statistical power than is achievable at individual sites and to use machine learning methods at scale. Once accurate models to predict complications are available, tools can be implemented for prevention, early detection, and intervention. For prediction tasks based on longitudinal data, a variety of methods based on recurrent neural network architectures can be leveraged [123] . To characterize patient subtypes, tensor factorization approaches have been shown to be quite effective for similar tasks [124] . Accurate machine learning-based CDS tool development requires algorithm optimization, a process that is greatly facilitated by a centralized data resource. Detailed medication and other clinical data in N3C also enable analyses of treatment pathways and patient response. These analyses can encompass medications received prior to and concurrent with the disease course as well as specific drug therapies, such as antivirals like remdesivir or hydroxychloroquine, tocilizumab, corticosteroids, broad-spectrum antibiotics, antifungals, and therapeutic anticoagulation. They can also provide evidence for best practices in clinical care such as supplemental oxygen, proning [125] , noninvasive positive pressure ventilation, invasive ventilation, and extracorporeal membrane oxygenation. N3C will be wellpositioned to generate immediately testable hypotheses about combinations and sequences of therapies, helping researchers to better design, prioritize, and analyze randomized trials. Analyses can take into account known outcome predictors including 1) medical history, comorbidities, and indicators such as hypertension, diabetes, and body mass index; 2) progression of vital signs; and 3) laboratory data such as electrolytes, markers of organ dysfunction, measures of inflammation, and indicators of possible thrombosis or approaching cytokine storm [126] . Investigators can develop tools to predict treatment response based on these analyses. Clinicians could match a patient's phenotype to one or more distinct groups of patients in the N3C dataset with known clinical outcomes. Such patient matching can be done at the point of care and provide real-time precision reference information for CDS, potentially based on patient similarity learning [127] . Furthermore, N3C facilitates the use of specific algorithms that can increase the unbiased selection of cohorts that have complete data, and which can be applied to most EHR studies [128, 129] . The size and national coverage of N3C data make it a unique source of COVID-19 data for population health segmentation and risk stratification. Segmenting the population for the risk of various outcomes (e.g., clinical, utilization) allows more efficient and effective resource allocation and interventions [130] as well as enable healthcare providers to measure and balance the risk of COVID-19 complications versus other clinical conditions and morbidities. For example, identifying patients who will benefit the most from the anticipated COVID-19 vaccination is of utmost importance [131] . N3C also provides a unique opportunity to enhance the role of data science and population health informatics in bridging the gap between clinical care, public health, and social services [136] ; thus, collectively aiming for predictive models promoting equity for all minorities [137] in the current and potential future COVID-19 outbreaks. Integrating data from multiple clinical research systems has proven effective for estimating potential research cohorts, identifying eligible patients, supporting current studies, and enabling new analyses [73, 138] . However, there are a number of caveats and N3C is no exception. Patient care data and the processes that generate and capture them differ from good research practices [139] . EHR data captured in real time are often wrong (e.g., incorrect diagnosis) or may have originated from a different patient. The available data may not convey the complete clinical picture due to fragmentation of patient care. For example, a patient's initial coronavirus test results may be performed by a government laboratory and not transmitted to the patient's EHR. Finally, patient care data rarely have completeness, reliability, granularity, and competent coding found in good, prospective clinical studies. This is not to say that research using the N3C Enclave will be flawed. The sheer magnitude of the dataset provides a buffer against the effects of systematic reporting bias. A number of methods can be used for considering data from multiple institutions, for example by applying methods used in metaanalysis [140] . habituation by healthcare organizations. By opening the door to a broad analytic community, we bring to the table new skill sets, diverse viewpoints, and additional opportunities for novel approaches. N3C is driving new standards in openness for collaboration on sensitive clinical data, and builds upon the infrastructure developed nationwide over the past decades. Specifically, the N3C model will continue to be refined and streamlined to provide a scalable approach that can be leveraged to help manage future waves of COVID-19, unforeseen novel diseases, and other major health crises, as well as long-standing challenges in healthcare. While N3C is focused on the US, this is a global pandemic and we must identify ways to collaborate with other international groups who are building similar infrastructure for a global approach; such conversations are underway [141, 142] . While no IRB review is required for the work presented in this manuscript, we describe the creation of a central IRB at JHU for use by member organizations. The central IRB protocol has been made public [143] . Contributing code • MMorrison Saltz: I have been instrumental in clinical support to develop code used to classify COVID subjects, their associated co-morbidities, treatment, medications and outcomes. This code will be used on the aggregated N3C data to perform similar analyses. In addition I have been participating in the Governance process, ensuring that access to the data be fair and equitable for all, and as accessible as possible to drive the best possible science around this pandemic. • T Schaffter: Organizing the EHR COVID-19 DREAM Challenge • TKL Schleyer: Detailed edits of draft of 6/15/2020. • S Setoguchi: I have critically reviewed the manuscript and provided edits/suggestions. I am leading NJ ACTS (Rutgers CTSA's) effort to contribute our EHR data to the consortium, • NH Shah: Lead efforts to prepare and contribute Stanford data to N3C on behalf of our CTSA • N Sharafeldin: Read-proofed and provided edits to the manuscript draft • E Sholle: Contributed to data harmonization workflow by providing AMC-OMOP stakeholder perspective • JC Silverstein: Participation in governance discussion and related documents and may be responsible for data contribution, and our team engagement with i2b2 to OMOP translation. • A Solomonides: Data contribution. I am very interested in creating a lay summary of the paper. Also using the paper for Data Governance permissions at NorthShore. • J Solway: Participating in data partnership and governance committee and edited manuscript • J Su: Participating in decision-making • V Subbian: I am part of two N3C workstreams (phenotype and analytics). I reviewed and provided feedback on the entire manuscript, including critical feedback on ethical issues related data sharing, governance, and analytics. • H Tak: Expansion of research field and data deployment • BW Taylor: I reviewed and edited the manuscript, participated in discussions for defining analytics environment, participating in work groups • AE Thessen: I contributed during governance meetings and editing manuscript text. • JA Thomas: I contributed with data collection, data curation, data quality assurance, data transformation, writing review and editing. COVID-19 Map. Johns Hopkins Coronavirus Resource Center Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period OpenSAFELY: factors associated with COVID-19 death in 17 million patients Launching PCORnet, a national patient-centered clinical research network Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers The FDA's Sentinel Initiative Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations International Electronic Health Record-Derived COVID-19 Clinical Course Profiles: The 4CE Consortium. Infectious Diseases (except HIV/AIDS) PCORnet COVID-19 Common Data Model Design and Results Machine Learning in Medicine Artificial intelligence in healthcare Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers Predicting the Future -Big Data, Machine Learning, and Clinical Medicine Unsupervised machine learning for the discovery of latent disease clusters and patient subgroups using electronic health records Federated Learning: Challenges, Methods, and Future Directions Systematic Review of Privacy-Preserving Distributed Machine Learning From Federated Databases in Health Care Federated Machine Learning: Concept and Applications Federated learning of predictive models from federated Electronic Health Records Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 The FAIR Guiding Principles for scientific data management and stewardship CTSA Program Hubs | National Center for Advancing Translational Sciences. National Center for Advancing Translational Sciences CTSA Program Hubs | National Center for Advancing Translational Sciences. National Center for Advancing Translational Sciences CD2H Human Tumor Atlas Network. Human Tumor Atlas Network Open Data Sharing in the 21st Century: Sage Bionetworks' Qualified Research Program and Its Application in mHealth Data Release Human Tumor Atlas Network. Human Tumor Atlas Network i2b2: Informatics for Integrating Biology & the Bedside i2b2: Informatics for Integrating Biology & the Bedside HIPAA Privacy Rule and Its Impacts on Research Certificates of Confidentiality (CoC) -Human Subjects | grants.nih.gov The Revised Common Rule's Cooperative Research Provision (45 CFR SMART IRB | National IRB Reliance Initiative Guidelines for Producing Useful Synthetic Data General and specific utility measures for synthetic data Methods for De-identification of PHI HIPAA Privacy Rule and Its Impacts on Research Metrics to Assess Value of Biomedical Digital Repositories: Response to RFI NOT-OD-16-133 Welcome to the Contributor Attribution Model -Contributor Attribution Model documentation Centers for Disease Control and Prevention. ICD-10-CM Official Coding Guidelines -Supplement Coding encounters related to COVID-19 Coronavirus Outbreak. 2020 Enabling Rapid Capture of Insights on Patients Infected with the Novel Coronavirus | The National Patient-Centered Clinical Research Network. The National Patient-Centered Clinical Research Network An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza. medRxiv Published Online First SARS-CoV-2 and COVID-19 related LOINC terms -LOINC. LOINC The Shared Health Research Information Network (SHRINE): a prototype federated query tool for clinical data repositories OHDSI -Observational Health Data Sciences and Informatics PCORnet Common Data Model v5.1 Specification Clinical classification and terminology: some history and current observations Classification, Ontology, and Precision Medicine Fast Healthcare Interoperability Resources (FHIR) The Pluripotent Rendering of Clinical Data for Precision Medicine Vulcan Accelerator Home -Vulcan Accelerator Data model considerations for clinical effectiveness researchers Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems Common Data Model Harmonization | HealthIT B2B Integration Platform for next-gen business connectivity | Adeptia Transparent reporting of data quality in distributed data networks A longitudinal analysis of data quality in a large pediatric data research network Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research The Data Book: Collection and Management of Research Data Quantifying clinical data quality using relative gold standards Execute and View Data Quality Checks on OMOP CDM Database PCORnet: The National Patient-Centered Clinical Research Network. PCORnet Data Checks v8. The National Patient-Centered Clinical Research Network Wikipedia contributors. Smoke testing (software). Wikipedia, The Free Encyclopedia. 2020 Explore B2B Process Automation Solutions for Integration Needs ETL Data Integration Software for Connecting Business Data Creates Descriptive Statistics Summary for an Entire OMOP CDM Instance Introduction COVID-19 TestNorm -A tool to normalize COVID-19 testing names to LOINC codes Balancing access to health data and privacy: a review of the issues and approaches for the future Facilitating phenotype transfer using a common data model PheValuator: Development and evaluation of a phenotype algorithm evaluator How Confident Are We About Observational Findings in Health Care: A Benchmark Study. Harvard Data Science Review Published Online First: 31 Improving reproducibility by using highthroughput observational studies with empirical calibration Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data Semantic integration of clinical laboratory tests from electronic health records for deep phenotyping and biomarker discovery Biomedical Data Translator Consortium. Toward A Universal Biomedical Data Translator Biomedical Data Translator Consortium. The Biomedical Data Translator Program: Conception, Culture, and Community Deconstructing the Translational Tower of Babel Leaf: an open-source, model-agnostic, data-driven web application for cohort discovery and translational biomedical research Recommendations to enhance rigor and reproducibility in biomedical research Synthea: An approach, method, and software mechanism for generating synthetic patients and the synthetic electronic health care record Synthesizing electronic health records using improved generative adversarial networks The validity of synthetic clinical data: a validation study of a leading synthetic data generator (Synthea) using clinical quality measures Membership Inference Attacks Against Generative Models … dedicated computer clients specially programmed to generate synthetic nonreversible electronic data records based on real-time electronic querying and methods of …. US Patent 10,235,537 Are Synthetic Data Derivatives the Future of Translational Medicine? RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 The extent and consequences of p-hacking in science Deep EHR: A Survey of Recent Advances in Deep Learning Techniques for Electronic Health Record (EHR) Analysis Tensor factorization toward precision medicine Prone Positioning in Awake, Nonintubated Patients With COVID-19 Hypoxemic Respiratory Failure COVID-19: consider cytokine storm syndromes and immunosuppression Deep Patient Similarity Learning for Personalized Healthcare Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation Published Online First: 17 External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research A proposed national research and development agenda for population health informatics: summary recommendations from a national expert workshop Comparing Population-based Risk-stratification Model Performance Using Demographic, Diagnosis and Medication Data Extracted From Outpatient Electronic Health Records Versus Administrative Claims COVID-19 and Health Equity-A New Kind of 'Herd Immunity A framework for identifying and mitigating the equity harms of COVID-19 policy interventions Hospitalization and Mortality among Black Patients and White Patients with Covid-19 Assessing Differential Impacts of COVID-19 on Black Communities Public and Population Health Informatics: The Bridging of Big Data to Benefit Communities Dissecting racial bias in an algorithm used to manage the health of populations The National Institutes of Health's Biomedical Translational Research Information System (BTRIS): design, contents, functionality and experience to date Caveats for the use of operational electronic health record data in comparative effectiveness research Recommendations for the Use of Operational Electronic Health Record Data in Comparative Effectiveness Research. eGEMs (Generating Evidence & Methods to improve patient outcomes) EMBL-EBI launches COVID-19 Data Portal ELIXIR support to COVID-19 research | ELIXIR National COVID Cohort Collaborative (N3C): A national resource for shared analytics We acknowledge the Oregon Clinical and Translational Research Institute for their guidance and review of N3C plans and regulatory processes as they unfolded.